跨KRAS突变型患者来源模型对泛RAS(ON)抑制剂daraxonrasib（RMC-6236）敏感性和耐药性的分子决定因素

CHAMPIONS Abstract Body: KRAS mutations define a major therapeutic opportunity across solid tumors but often align with limited response durability and resistance to targeted therapies. Daraxonrasib (RMC-6236), a selective pan-RAS(ON) inhibitor, demonstrates activity across KRAS G12X-mutant tumors; however, the molecular and clinical features governing sensitivity or promoting resistance remain incompletely understood. We screened a >50-model KRAS-mutant PDX cohort spanning NSCLC (n=16), colorectal cancer (n=19), and pancreatic ductal adenocarcinoma (n=19). Models reflect clinically relevant KRAS variants and diverse co-mutational landscapes, accompanied by pre-treatment patient histories, enabling classification of responders and non-responders through integration of molecular and clinical contexts. Tumors were evaluated for intrinsic response, and longitudinal sampling captured acquired-resistance outgrowths for subsequent genomic analysis.  We performed integrated NGS (omics?) analyses on (i) baseline data from responding vs non-responding models, (ii) resistant tumors emerging after initial regression, and (iii) associations with prior patient treatments.  Daraxonrasib produced a broad range of activity across the array of models screened. Heterogeneity in the depth and durability of responses correlated with KRAS allele type, co-driver mutations, and specific pre-treatment exposures. These studies establish an annotated, translational system for defining determinants of RAS(ON) inhibitor response that shape resistance and inform rational therapeutic combination strategies.